Clinical trial NCT06890637: A Study to Evaluate the Effect of Fecal Transplant and Dietary Changes on Disease Activity in Patients With Crohn Disease on Advanced Therapies
Official title: Efficacy of Microbiome Manipulation Strategies (Fecal Microbial Transplant or Crohns Disease Exclusion Diet or Both) With Advanced Therapies (BiOlOgics and Small Molecules) to Break the Therapeutic Ceiling in Active Crohns Disease (BOOST-CD): A Multicenter Double Blind Factorial Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Crohns Disease
Keywords: Randomized Controlled Trial
Factorial Design
Fecal Microbial Transplantation
Crohns disease exclusion diet
Crohns disease
Advanced therapy
Lead sponsor: All India Institute of Medical Sciences
Sponsor class: OTHER
First posted: 2025-03-24
Enrollment: 168
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: Advanced therapies including biologics and small molecules target specific inflammatory pathways. IBD's multifactorial etiology means that blocking a single pathway may not be sufficient for all patients. Even when combination of advanced therapies are used, the incremental benefits often diminish, reflecting the therapeutic ceiling. Furthermore, safety concerns also limit the potential to push beyond this ceiling. Increasing the dose or adding more immunosuppressive agents can lead to a higher risk of infections, malignancies, and other adverse effects, making it impractical to continually intensify treatment. Understanding the therapeutic ceiling in IBD highlights the need for innovative approaches that go beyond current strategies. Given the diverse microbial and immunological landscapes in IBD combining fecal microbiota transplantation (FMT) and Crohn's Disease Exclusion Diet (CDED) with advanced therapies represents a promising approach to break the therapeutic ceiling in CD. This strategy leverages the complementary mechanisms of action of FMT/CDED and advance therapies, potentially offering a more comprehensive treatment modality that addresses the complex and multifactorial nature of IBD. FMT involves the transfer of gut microbiota from a healthy donor to a patient, aiming to restore a balanced microbial community in the intestines. This can help modulate the immune system and reduce inflammation, which are central to Crohn's disease pathology. This study seeks to provide evidence on whether addition of microbiota manipulation by FMT and CDED offers additional benefits when used alongside advance therapies in active CD. The findings from this RCT are expected to significantly enhance treatment strategies, ensuring that patients receive the most effective and appropriate care based on robust scientific evidence. This multi-center double blind placebo-controlled RCT will randomize patients in 1:1:1:1 ratio to FMT, CDED and advance therapy vs sham FMT with advance therapy and CDED vs FMT, Advance therapy and sham diet vs Advance therapy with sham FMT and sham diet for induction and maintenance of remission in patients of active Crohn's disease. Randomization will be held centrally to ensure concealment of allocation. Random numbers will be generated by computerized random number schedule (The RAND), and the randomization list and numbered packing of the intervention will be prepared by a person not involved in the study. Randomization will be performed using permuted blocks of 8. Both the patient and the investigator will be blinded to the intervention

Detailed description: This is a multicenter, double-blind, factorial randomized controlled trial (RCT) evaluating the efficacy of microbiome manipulation strategies in patients with active Crohn's Disease (CD) undergoing advanced therapy (biologics or small molecules). The study will be conducted across six clinical centers in India, with an additional center designated for microbiome analysis.

Randomization and Blinding:

Randomization: Centralized, computer-generated randomization using permuted blocks of 8, 12, and 16 to ensure equal distribution across intervention arms.

Stratification: Not more than 1/3rd patients should be biological therapy exposed

Blinding:

The blinded team includes patients and principal investigators. Endoscopists administering FMT/sham FMT and dietitians providing dietary counseling will be unblinded

Sham-Control Methods:

FMT Sham: Sterile clean water infusions via colonoscopy. Diet Sham: Dietary counseling without any modification

Intervention Arms:

Patients are randomized into one of four treatment groups:

FMT + CDED + Advanced Therapy (Group A) FMT + Sham Diet + Advanced Therapy (Group B) Sham FMT + CDED + Advanced Therapy (Group C) Sham FMT + Sham Diet + Advanced Therapy (Group D)

Fecal Microbiota Transplantation (FMT):

FMT Route: Administered via colonoscopy.

FMT Schedule:

Induction Phase: Weeks 0, 2, and 6. Maintenance Phase: Every 8 weeks (weeks 10, 18, 26, 34, 42) for responders.

Preparation:

Donor Selection: Multi-donor approach with prescreening FMT Processing: 50 g stool freshly prepared and instilled within 4 hours.

Delivery Locations:

Week 0 (Bowel Preparation): Right colon/terminal ileum. Weeks 2 and 6 (No Bowel Preparation): Left colon. Crohn's Disease Exclusion Diet (CDED)

Diet Structure:

Induction Phase (Weeks 0-6): Elimination of specific pro-inflammatory dietary components.

Maintenance Phase (Weeks 6-48): Gradual reintroduction of certain food groups. Monitoring: Adherence tracked using the IBD NutriCare app, diet recall logs, and DietCal software.

Sham Diet: Patients follow a standard healthy diet with general dietary counseling.

Assessments and Data Collection Baseline Assessments (Week 0) Clinical Data: Crohn's Disease Activity Index (CDAI), stool frequency, rectal bleeding, and symptom tracking.

Laboratory Tests:

Hemogram, renal/liver function tests, blood glucose. Inflammatory Markers: C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), fecal calprotectin (FCP).

Microbiome Analysis: Stool samples stored at -80°C for sequencing.

Endoscopic Evaluation:

Scoring: Simple Endoscopic Score for CD (SES-CD). Blinded Central Review: Videos assessed by two independent readers; discrepancies adjudicated by a third reader.

Histology: Biopsies analyzed using DCA score (Distribution Chronicity and Activity).

Follow-up Assessments

Visit Schedule:

Induction Phase: Weeks 2, 4, 6, and 10. Maintenance Phase: Every 8 weeks (weeks 18, 26, 34, 42, and 48). Clinical Assessments: CDAI, PRO2 symptom tracking, medication adherence checks. Endoscopy: Week 10 and Week 48; central scoring of videos. Diet Adherence: Assessed at weeks 2, 4, 6, and 10, then every 8 weeks. Microbiome Sampling: Stool samples collected at weeks 10 and 48. Safety Monitoring and Adverse Events

Adverse Event (AE) Classification:

CTCAE Grading (Grade 1-5) for treatment-related AEs. Serious Adverse Events (SAEs): Hospitalization, life-threatening events, or disability.

Safety Monitoring Plan:

Pre-procedural safety checks for each FMT session. Immediate post-FMT monitoring (48 hours). Late safety assessments (14 days post-FMT, then every visit). Unblinding Procedure: Allowed only for SAE management with DSMB approval. Data Management and Statistical Analysis

Electronic Data Capture (EDC):

Platform: REDCap database with tiered access permissions. Audit Trails: Secure logs of data entry and modification.

Dietary Data Processing:

IBD NutriCare app logs converted into macronutrient composition reports. Adherence scoring based on 80% compliance threshold.

Microbiome Data Processing:

Samples sequenced at IIIT-Delhi, analyzed for diversity indices and metabolic pathways.

Statistical Plan:

Primary Analysis: Intention-to-treat (ITT) and per-protocol (PP) analyses. Longitudinal Modeling: Mixed-effects models for repeated measures.

Effect Size Estimation:

Sample size: 168 patients (42 per arm).

Eligibility criteria: Inclusion Criteria:

1. Patients with active Crohn disease in whom FMT is feasible
2. Active Crohn's disease who are candidates for advanced therapy (steroid refractory, Immunomodulator intolerant or refractory and moderately severe disease at the time of inclusion) or patients who have an intolerance to or have lost response to advanced therapies must have had their last treatment at least five half-lives prior randomization.
3. Aged between 18-75 years
4. CDAI greater than 150 and/or SES-CD equal or greater than 6 (or equal or greater than 4 if isolated ileal disease)

Exclusion Criteria:

1. Patients in remission (CDAI less than 150)
2. Stricturing disease (non-passable stricture) in whom FMT is not feasible
3. Fistulising phenotype or Perianal fistula or abscess
4. Isolated L4 disease
5. Active TB or Sepsis
6. Pregnant or lactating women
7. Patients with co-morbidities like CAD/CLD/CKD
8. Previous surgery for CD
9. Declining consent or not willing for FMT or diet advice
10. Patients with current or recent history of clinically severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, metabolic, endocrine, pulmonary, cardiac, or neurological disease.
11. Positive assay or stool culture for pathogens (ova and parasite examination, bacteria) or positive test for Clostridioides difficile toxin at screening#
12. Patients infected with human immunodeficiency virus (HIV) #The patients with positive assay will be treated appropriately and tests will be repeated.

Those with negative assay and persistent activity will be included in the study

Primary outcomes:
measure: Proportion of patients with clinical remission and endoscopic response at week 10
timeFrame: 10 weeks
measure: Proportion of patients with clinical remission and endoscopic remission at week 10
timeFrame: 48 weeks
Secondary outcomes:
measure: Proportion of patients with clinical response at Week 10
timeFrame: 10 weeks
measure: Proportion of patients with PRO2 Remission at Week 10
timeFrame: 10 weeks
measure: Proportion of patients with endoscopic response at Week 10
timeFrame: 10 weeks
measure: Fecal microbiome and metabolite signature between responders and non-responders at week 10
timeFrame: 10 weeks
measure: Proportion of patients with biomarker remission at Week 10
timeFrame: 10 weeks
measure: Proportion of patients with adverse events at Week 10
timeFrame: 10 weeks
measure: Proportion of patients with clinical response at Week 48
timeFrame: 48 weeks
measure: Proportion of patients with PRO2 remission at Week 48
timeFrame: 48 weeks
measure: Proportion of patients with endoscopic response at Week 48
timeFrame: 48 weeks
measure: Proportion of patients with Endoscopic remission at Week 48 weeks
timeFrame: 48 weeks
measure: Proportion of patients with corticosteroid-free clinical remission at Week 48
timeFrame: 48 weeks
measure: Fecal microbiome and metabolite signature between responders and non-responders at Week 48
timeFrame: 48 weeks
measure: Proportion of patients with biomarker remission at Week 48
timeFrame: 48 weeks
measure: Proportion of patients with adverse event at Week 48
timeFrame: 48 weeks
measure: Proportion of patients with adverse event at Week 6
timeFrame: 6 weeks
measure: Proportion of Patients Experiencing Adverse Events at Week 26
timeFrame: 26 weeks
Other outcomes:
Locations:
city: New Delhi
country: India
facility: Department of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences
state: Delhi
city: Kochi
country: India
facility: Department of Gastroenterology, Lisie Hospital
state: Kerala
city: Mumbai
country: India
facility: Lokmanya Tilak Municipal General Hospital and Lokmanya Tilak Municipal Medical College, Sion
state: Maharashtra
city: Ludhiana
country: India
facility: Department of Gastroenterology, Dayanand Medical College
state: Punjab
city: Varanasi
country: India
facility: Department of Gastroenterology, Institute of Medical Sciences
state: Uttar Pradesh
city: Chandigarh
country: India
facility: Department of Gastroentrology, Postgraduate Institute of Medical Education and Research
Study officials:
affiliation: Department of Gastroenterology, AIIMS, New Delhi
name: Prof Vineet Ahuja, DM Gastroenterology
role: PRINCIPAL_INVESTIGATOR
References: